United Kingdom
Constructive Bio, founded in 2021 and headquartered in the United Kingdom, is making significant strides in the biotechnology sector by exploring the potential of genome rewriting. Guided by the slogan, "Realising the potential of genome rewriting to drive the next generation of bioprocesses and biopharmaceuticals," this innovative company is poised to reshape the biopharmaceutical landscape.
Originating as a spin-out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge, Constructive Bio leverages cutting-edge technology to reprogram the genetic code. This enables the biosynthesis of novel enzymes, pharmaceuticals, and biomaterials that nature could not produce independently.
In March 2026, the company secured a significant £15.00M in Early VC investment, underscoring investor confidence in their vision and technological prowess. As they continue to expand their team and capabilities, Constructive Bio is set to become a pivotal player in the field of modern biotechnology.
